Artificial Intelligence has already been applied to all kinds of businesses from tech to marketing, and the pharmaceutical industry is no different. Sanofi (SNY) CEO Paul Hudson talks with Yahoo Finance's Anjalee Khemlani about how A.I. has been integrated into their drug development pipeline.
Hudson explains that with A.I. it's possible to do "sophisticated algorithmic work" which will in turn allow a study to be "six or 12 months ahead of what you could do before having those tools, and that means... you can submit it to the regulators early and of course then get it to patients earlier".
